Jove
Visualize
联系我们
这页已由机器翻译。其他页面可能仍然显示为英文。View in English
  1. 首页
  3. 研究领域
  5. 生物医学和临床科学
  7. 心血管医学和血液学
  9. 心脏病 (包括心血管疾病)
  11. 根据经皮冠状动脉干预的患者血小板功能测试进行量身定制的抗血小板治疗的长期结果:一项5年后期的队列研究
  1. 首页
  3. 研究领域
  5. 生物医学和临床科学
  7. 心血管医学和血液学
  9. 心脏病 (包括心血管疾病)
  11. 根据经皮冠状动脉干预的患者血小板功能测试进行量身定制的抗血小板治疗的长期结果:一项5年后期的队列研究

相关实验视频

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

根据经皮冠状动脉干预的患者血小板功能测试进行量身定制的抗血小板治疗的长期结果:一项5年后期的队列研究

Emanuele Cecchi1, Andrea Grasso Granchietti2,3, Claudia Assenza4

  • 1General Cardiology Unit, Department of Cardiac Thoracic and Vascular Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Heart and vessels
|August 21, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

血小板功能测试 (PFT) 有助于针对经皮冠状动脉干预 (PCI) 的患者进行双重抗血小板治疗. 与标准治疗相比,以PFT为指导的方法在5年内显著减少了不良临床事件.

科学领域:

  • 心脏病学
  • 药理学

背景情况:

  • 双抗血小板治疗 (DAPT) 是皮肤冠状动脉干预 (PCI) 后的二次预防标准.
  • 随着抗血小板药物的发展和出血风险的认识,需要优化DAPT策略.
  • 血小板功能测试 (PFT) 提供了个性化抗血小板选择的方法.

研究的目的:

  • 评估PFT在指导PCI患者选择DAPT的临床效用.
  • 在5年的随访期间,比较PFT指导和标准DAPT之间的缺血和出血事件.

主要方法:

  • 分析了一组490名冠状动脉综合征患者进行PCI.
  • 患者接受了PFT指导的DAPT (68. 4%) 或标准DAPT.
  • 主要终点是净不良临床事件 (NACE),死亡率,心脏病发作,中风或严重出血 (BARC尺度) 的组合.

主要成果:

  • 以PFT为指导的组显示NACE的发病率明显较低 (33.7%对43.9%,p=0.02).
  • 支架的总长度和左主冠状动脉疾病是NACE的独立风险因素.
  • 在随访期间,N-STEMI或不稳定的心痛诊断增加了不良事件的风险.

结论:

关键词:
双重抗血小板治疗穿皮冠状动脉干预血小板功能测试定制的抗血栓治疗

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

相关实验视频

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  • 在PCI患者中,以PFT为指导的定制抗血栓治疗方法是安全有效的.
  • 以PFT为指导的DAPT是一种可行的策略,特别是对于高出血风险的患者.
  • 个性化抗血小板治疗可以优化PCI患者的治疗结果.